These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 7502695)

  • 1. Do the suppression criteria in GnRH-a cycles predict in vitro fertilization outcome?
    Senöz S; Gülekli B; Turhan NO; Ozakşit G; Odabaşi AR; Oral H; Ozcan U; Gökmen O
    Gynecol Endocrinol; 1995 Jun; 9(2):91-6. PubMed ID: 7502695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of different ovarian stimulation protocols for in vitro fertilization.
    Pados G; Tarlatzis BC; Bontis J; Lagos S; Papadimas J; Spanos E; Mantalenakis S
    Gynecol Endocrinol; 1995 Jun; 9(2):103-12. PubMed ID: 7502685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
    Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
    Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
    Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
    Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of a combination administration of gonadotropin-releasing hormone agonist and gonadotropins for controlled ovarian hyperstimulation in IVF program.
    Chang YS; Kim SH; Shin CJ; Kim JG; Moon SY; Lee JY
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):337-45. PubMed ID: 2129188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
    Kan O; Simsir C; Atabekoglu CS; Sonmezer M
    Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilization.
    Droesch K; Muasher SJ; Brzyski RG; Jones GS; Simonetti S; Liu HC; Rosenwaks Z
    Fertil Steril; 1989 Feb; 51(2):292-7. PubMed ID: 2492234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled ovarian hyperstimulation for in vitro fertilization using buserelin and gonadotropin in patients with previous failed cycles.
    Loong EP; Tam PP; Chiu TT; Chan MY; Panesar NS; Lau J
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):297-300. PubMed ID: 2129187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclusion of standard and low-dose gonadotropin releasing hormone-analog (short protocol) in controlled ovarian hyperstimulation regimens in normogonadotropic patients aged 40-48 years who are undergoing in vitro fertilization.
    Avrech OM; Orvieto R; Pinkas H; Sapir-Rufas O; Feldberg D; Fisch B
    Gynecol Endocrinol; 2004 Nov; 19(5):247-52. PubMed ID: 15726912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of gonadotropins in follicular development and their use in ovulation induction protocols for assisted reproduction.
    Zafeiriou S; Loutradis D; Michalas S
    Eur J Contracept Reprod Health Care; 2000 Jun; 5(2):157-67. PubMed ID: 10943580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of LH-containing gonadotropin stimulation on euploidy rates in preimplantation embryos: antagonist cycles.
    Weghofer A; Munné S; Brannath W; Chen S; Barad D; Cohen J; Gleicher N
    Fertil Steril; 2009 Sep; 92(3):937-942. PubMed ID: 18774557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization.
    Yang TS; Wang BC; Chang SP; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jun; 55(6):452-6. PubMed ID: 7634183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clomiphene citrate and hMG: an alternative stimulation protocol for selected failed in vitro fertilization patients.
    Benadiva CA; Davis O; Kligman I; Liu HC; Rosenwaks Z
    J Assist Reprod Genet; 1995 Jan; 12(1):8-12. PubMed ID: 7580013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ovarian response and pregnancy rates in in vitro fertilization, gamete intrafallopian transfer, and in vivo fertilization therapies after combined gonadotropin-releasing hormone agonist/human menopausal gonadotropin stimulation.
    Lindner C; Braendle W; Lichtenberg V; Köhler S; Bettendorf G
    Gynecol Obstet Invest; 1990; 29(2):140-4. PubMed ID: 2139861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.